AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02535221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin+CTX+5-Fu
Description: Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
Study NCT01702259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia Scanner device (GLS)
Description: The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
Study NCT01702259 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo device
Description: Inactive Erchonia GLS.
Study NCT00792337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 10 mg per oral once daily for 8 weeks
Study NCT00792337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1-6-12
Description: 1 table per day for 8 weeks
Study NCT01787032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: tablet
Study NCT01787032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: tablet
Study NCT01787032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: tablet
Study NCT03658252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted education
Description: Educational video developed by the hospital, addressing common misconceptions of topical steroids. A patient information leaflet on topical steroids
Study NCT03658252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online disease specific forum
Description: An invitation to join an online moderated disease specific social forum
Study NCT02333318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 injection
Description: Colorless, transparent liquid in water for injection
Study NCT02333318 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study NCT01628367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone Graft Placement
Description: Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
Study NCT01628367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Membrane placement
Description: A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
Study NCT01628367 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Collagen plug placement
Description: A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
Study NCT01628367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medications
Description: Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
Study NCT01628367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medications
Description: Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
Study NCT02594800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
Study NCT03883802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foxy-5
Description: Lyophilized powder for solution for intravenous infusion
Study NCT03883802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: 6 months treatment regimen
Study NCT03883802 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: 6 months treatment regimen
Study NCT02594800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
Study NCT03100721 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PNE+Physiotherapy
Description: Physiotherapy cover kinesitherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
Study NCT03100721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physiotherapy cover kinesitherapy and exercises techniques.
Study NCT03883802 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumour resection (colon cancer surgery)
Description: Surgical removal of patients colon cancer
Study NCT03883802 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumour resection (colon cancer surgery)
Description: Surgical removal of patients colon cancer
Study NCT00354692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate and Iron sucrose
Study NCT04671082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolperisone Hydrochloride
Description: TID
Study NCT04671082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TID
Study NCT05111106 — intervention group
Intervention type: DEVICE
Intervention: Symfony IOL
Description: Implantation of Intraocular lens with extended depth of focus.
Study NCT01812330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: After 600mg loading dose, 75mg or 150mg Qd
Study NCT01812330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg Bid
Study NCT02065609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-Trastuzumab Human Dosimetry and Safety
Description: PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
Study NCT02065609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 Positive Lesion Detection and Safety
Description: Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
Study NCT04105751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel Communication System
Description: Small hand held device that aids in answering questions. Used in conjunction with a tablet computer.
Study NCT00554398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0518 400mg twice a day
Description: Raltegravir, MK-0518
Study NCT01744678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blue-wavelength enriched ceiling light
Description: Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
Study NCT01744678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mild exercise
Description: Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
Study NCT01749592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implant
Description: Surgical implantation of a cochlear implant device
Study NCT03594149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 500 mg/d p.o.
Study NCT02295007 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: text message
Study NCT00600041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: 80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
Study NCT04007705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory and low FODMAPs diet
Description: Exemption of the intake of potentially inflammatory foods, namely gluten, dairy and processed foods, over a consecutive period of 3 months. During the first month, a low FODMAPs diet will be implemented, along with the anti-inflammatory diet, followed by the reintroduction of all fruits and vegetables over a consecutive period of 2 months.
Study NCT04007705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General healthy eating
Description: Healthy eating counseling according to the World Health Organization
Study NCT00600041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical infusion manner like experimental arm
Study NCT00462735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 250 mg/m2 on Day 1 after the first dose of radiation was administered to all patients
Study NCT00462735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: 500 mg orally every 12 hours with the morning dose administered 2 hours before radiation
Study NCT01350570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
Study NCT01350570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture group2
Description: Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
Study NCT00462735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: continuous-infusion 5-FU at a dose of 600 mg/m2 daily for 120 hours
Study NCT00462735 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy was administered at 1.5 Gy per fraction twice daily with treatments separated by at least 6 hours on Days 1 through 5 on an alternating week schedule.~Radiation was delivered with intensity-modulated radiation therapy (IMRT) planning for all patients.
Study NCT01846715 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Implantation of SRC
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #1
Description: B\&L Renu Fresh Multipurpose Solution
Study NCT00655109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine
Description: Ophthalmic solution
Study NCT00655109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: Nasal spray
Study NCT00655109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Nasal spray
Study NCT00655109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial tears
Description: Ophthalmic Solution
Study NCT00898521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DGD
Description: DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.~Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).~Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.~The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.~DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.~DGD should not be applied more than twice to the same burn wound area.
Study NCT01714076 — intervention group
Intervention type: OTHER
Intervention: cohort isolation
Description: all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
Study NCT01080404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: A standardized laparoscopic gastric bypass using Roux-en-Y technique
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multipurpose Solution #1
Description: B\&L Renu Fresh Multipurpose Solution
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #2
Description: Optifree Replenish Multipurpose Solution
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multipurpose Solution #2
Description: Optifree Replenish Multipurpose Solution
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mutlipurpose Solution #3
Description: Ciba ClearCare Multipurpose Solution
Study NCT01350570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture group3
Description: All acupoints used in acupuncture group1 and group2 will be used in this group.
Study NCT01350570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loperamide
Description: Loperamide will be used in this group for a dose of 2mg a time, three time a day.
Study NCT04382287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remin Pro® and MI Paste Plus®
Description: Te toothastes were applied at home twice a day over the six anterior upper primary teeth
Study NCT04382287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remin Pro® and MI Paste Plus®
Description: Te toothastes were applied at home twice a day over the six anterior upper primary teeth
Study NCT02341898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational programme for all nurses
Study NCT02341898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and structured support for nominated key nurses
Study NCT02341898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facultative train-the-trainer module for key nurses
Study NCT02341898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed study material
Study NCT02341898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed study material
Study NCT02341898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive material (poster, mugs etc.)
Study NCT04123626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QR-1123
Description: unilateral IVT injection
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mutlipurpose Solution #3
Description: Ciba ClearCare Multipurpose Solution
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multipurpose Solution #4
Description: Saline Solution
Study NCT01335750 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multipurpose Solution #4
Description: Saline Solution
Study NCT04126265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial intelligence assisted colonoscopy
Description: The colonoscopy is connected to the real-time polyp detection system. If the polyp is detected by enteroscopy, the alarm will be given.
Study NCT03250039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 14C labeled PF-04965842
Study NCT03250039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Absolute Bioavailability
Description: Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
Study NCT03094286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
Study NCT04140201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 40mg
Description: Drugs that lower lipid level
Study NCT04140201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 200mg
Description: Drugs that lower lipid levels
Study NCT04140201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: Drugs that lower lipid levels
Study NCT03504241 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor-derived Mesenchymal Stromal Cells
Description: These MSCs are a cellular product derived from bone marrow and propagated ex vivo using FDA-approved, clinically applicable methods. Their use in kidney transplantation has been associated with a good safety profile.
Study NCT04123626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham procedure
Description: Sham procedures (i.e. no penetration of the globe) closely mimic the active injection and serve to mask subjects to treatment assignment
Study NCT02989324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MisoprostoL
Description: Vaginal MisoprostoL
Study NCT03504241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Alemtuzumab, 30 mg, given once intravenously (IV) over three hours. The infusion of alemtuzumab shall begin within 24 hours of transplantation surgery and shall be given prior to the first dose of belatacept.
Study NCT03504241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Belatacept will be given as an intravenous (IV) infusion of 10mg /kg over 1 hour on transplantation postoperative Day 0, Days 5 and 14, then every 2 weeks (± 2 days) for 5 additional doses.Thereafter, belatacept will be given once every 4 weeks (± 5 days) at 10 mg/kg through 24 weeks post-transplant, then at 5 mg/kg every 4-weeks until the participant is evaluated for belatacept discontinuation.
Study NCT03504241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Rapamune® (sirolimus) (Wyeth Pharmaceuticals Inc., Philadelphia, PA) will be started on transplantation postoperative day 1 at a dose of 2 mg/day orally and adjusted to maintain goal 24-hour trough levels of 8-10 ng/ml. Participants who experience grade 3 sirolimus toxicity will undergo dose reduction.
Study NCT03504241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Per protocol, and, only permitted in cases of sirolimus intolerance.
Study NCT03504241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate acid
Description: Per protocol, and, only permitted in cases of sirolimus intolerance.
Study NCT03504241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Per protocol, and, only permitted in cases of sirolimus intolerance.
Study NCT05562362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RE-021, sparsentan
Description: RE-021, sparsentan - Subjects will be randomized 1 of 3 dose level
Study NCT00091351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00091351 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT00524368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir (DRV)
Description: DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
Study NCT00524368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (rtv)
Description: DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
Study NCT01545986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.